ReviewObesity science & practice2026
Recent Insights Into Circulating Adipokines in Obesity: Systematic Review and Meta-Analysis.
Review in Obesity science & practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Celastrol at the obesity-cancer interface: critical appraisal of molecular mechanisms, preclinical evidence, and translational barriers.Molecular biology reports · 2026Review
- Adipokine-mediated metabolic responses across BMI in acute myocardial infarction.BMC cardiovascular disorders · 2026Article
- Review
- Recent Insights Into Circulating Adipokines in Obesity: Systematic Review and Meta-Analysis.Obesity science & practice · 2026Review
- Adipokine, endocrine, and fibrinolysis-related alterations across abdominal obesity and metabolic syndrome phenotypes in young adults.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adipokines are dysregulated in obesity and exacerbate proinflammatory conditions. Although several studies have investigated adipokine levels in obesity, their findings have been inconsistent, leaving the precise nature of these alterations uncertain. This systematic review and meta-analysis aimed to provide an updated overview of circulating adipokines, particularly adiponectin, leptin, fibroblast growth factor 21 (FGF21), growth differentiation factor 15 (GDF15), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) in the context of obesity. Methods: This study adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and PROSPERO registration (CRD42024525103). PubMed/MEDLINE, Scopus, and Results: From 2378 records, 30 and 16 studies were included in the review and meta-analysis, respectively. Adiponectin levels were significantly lower in persons with obesity than in those with normal weight ( Conclusions: Adiponectin, leptin, TNF-α, and FGF21 show consistent directionality and may serve as robust biomarkers in obesity-related risk profiling. Conversely, GDF15 and IL-6 exhibit context-dependent variability. Further prospective cohort studies are warranted to better understand these adipokines, as persons with normal weight may still be at a high risk of cardiometabolic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.